ESCRS - Augmented Reality: New tool in ophthalmology

Augmented Reality: New tool in ophthalmology

New device provides visual rehabilitation for AMD patients

Augmented Reality: New tool in ophthalmology
Leigh Spielberg
Leigh Spielberg
Published: Monday, February 1, 2021
Linda Lam, MD, MBA
What is augmented reality? Is it the same as virtual reality? “No,” said Dr Linda A Lam MD, MBA, Associate Professor at the University of Southern California Keck School of Medicine, Los Angeles, California, USA, during her presentation at EURETINA 2020 Virtual. “Whereas virtual reality replaces the real world by shutting out the physical world and providing a completely immersive experience, augmented reality enhances the real world, providing a digital overlay over real-world surroundings. Dr Lam said that augmented reality (AR) might be an ideal modality to help patients with age-related macular degeneration (AMD), and explained how a new glasses-like device, the Oculenz, helps reduce central scotomas’ negative effects on patients’ vision. “The Oculenz is revolutionary in that it allows for pixel mapping around the blind spot,” she said. “Currently available devices for patients with AMD use VR systems, which are generally heavy, tethered and intended for indoor use only. They do not provide peripheral vision and thus do not allow users to walk around with the device,” she explained. On the other hand, Oculenz, developed by Ocutrx, uses AR technology for patients with central vision loss. How does this work? “The patient first takes a visual field test while wearing the headset,” she explained. “Based on the results of this test, the device maps the areas that the patient cannot see, creating a scotoma marker.” This scotoma marker shows remarkable correspondence when overlaid by fundus autofluorescence; the scotoma marker fits nearly perfectly on the zones of retinal damage. Step 2 is called pixel mapping. “The scotoma marker data is stored in the processing unit. 4K cameras produce videos from the real world, which are processed to move the images outside of the scotoma,” said Dr Lam. These images are then projected on to the inside of the glasses, to be seen by the healthy retina. In Step 3, infrared lights illuminate eye gaze, allowing eye-tracking cameras to follow eye movement. “This eye-tracking keeps the scotoma marker in line with the augmented image on the glasses lens. This allows Step 4 to occur, in which the image is moved away from the scotoma to areas of healthy retina. Additionally, the device sends visual field test results to the patient’s physician, alerting the physician if the scotoma changes, indicating possible disease progression. “The initial pilot trial of five patients showed a mean improvement from 20/200 to 20/63, with an average improvement of 17 to 19 letters. This new device is anticipated to be available in mid-2021. Linda A Lam: linda.lam@med.usc.edu
Tags: augmented reality
Latest Articles
Simulators Benefit Surgeons and Patients

Helping young surgeons build confidence and expertise.

Read more...

Diamonds in the Rough

The push for inclusivity in ophthalmology.

Read more...

Making Female Leadership More than a Moment

A remarkable global confluence of women in key positions.

Read more...

ESCRS Talks Technology at AAO

Europe adopts technological advances, US still waiting for lenses and lasers.

Read more...

Sorting Out Simultaneous Vision IOLs

The ESCRS Eye Journal Club discuss a new landmark paper on IOL classification and the need for harmonisation of terminology for presbyopic IOLs.

Read more...

Big Advantages to Small-Aperture IOLs

Small-aperture IOLs offer superior image quality with increased range of focus.

Read more...

Prioritising Self-Care

Benefits of maintaining physical, emotional, and mental health extend beyond the personal sphere.

Read more...

Valuing Clinical Trial Design

How inclusivity and diversity can enhance scientific accuracy in research.

Read more...

Knowing Iris Repair: Using Iridodiathermy in Iris Surgery

Prepare for decentred pupils and uneven irides in multiple situations.

Read more...

Neuroprotectant Treatment for MacTel Type 2

Intravitreal implant releasing ciliary neurotrophic factor found safe and effective in pivotal trials.

Read more...